WO2010073078A3 - Heterocyclic compounds as hdac inhibitors - Google Patents

Heterocyclic compounds as hdac inhibitors Download PDF

Info

Publication number
WO2010073078A3
WO2010073078A3 PCT/IB2009/007707 IB2009007707W WO2010073078A3 WO 2010073078 A3 WO2010073078 A3 WO 2010073078A3 IB 2009007707 W IB2009007707 W IB 2009007707W WO 2010073078 A3 WO2010073078 A3 WO 2010073078A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compounds
hdac inhibitors
hdac
conditions
polymorphs
Prior art date
Application number
PCT/IB2009/007707
Other languages
French (fr)
Other versions
WO2010073078A2 (en
Inventor
Gopalan Balasubramanian
Sridharan Rajagopal
Suresh Rathinasamy
Narasimhan Kilambi
Praveen Rajendran
Shridhar Narayanan
Original Assignee
Orchid Research Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Research Laboratories Ltd. filed Critical Orchid Research Laboratories Ltd.
Publication of WO2010073078A2 publication Critical patent/WO2010073078A2/en
Publication of WO2010073078A3 publication Critical patent/WO2010073078A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to heterocyclic compounds of the general formula (I) their derivatives, analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, metabolites, prodrugs, pharmaceutically acceptable salts and compositions thereof. Also included is method for treatment of proliferative conditions and cancer, conditions mediated by HDAC, in a mammal comprising administering an effective amount of compound formula (I) as described above.
PCT/IB2009/007707 2008-12-22 2009-12-10 Heterocyclic compounds as hdac inhibitors WO2010073078A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3220/CHE/2008 2008-12-22
IN3220CH2008 2008-12-22

Publications (2)

Publication Number Publication Date
WO2010073078A2 WO2010073078A2 (en) 2010-07-01
WO2010073078A3 true WO2010073078A3 (en) 2010-11-04

Family

ID=42288188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/007707 WO2010073078A2 (en) 2008-12-22 2009-12-10 Heterocyclic compounds as hdac inhibitors

Country Status (1)

Country Link
WO (1) WO2010073078A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592685A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
EP2874625B1 (en) 2012-07-17 2017-05-17 Sanofi Use of vegfr-3 inhibitors for treating hepatocellular carcinoma
JP2020529432A (en) 2017-08-04 2020-10-08 アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. Microbial-induced amyloid inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073229A1 (en) * 2004-01-31 2005-08-11 Sanofi-Aventis Deutschland Gmbh 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
EP1564210A1 (en) * 2002-11-20 2005-08-17 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2008030120A1 (en) * 2006-09-07 2008-03-13 Auckland Uniservices Limited A method for the fluorescent detection of nitroreductase activity using nitro-substituted aromatic compounds
WO2010064735A1 (en) * 2008-12-05 2010-06-10 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1564210A1 (en) * 2002-11-20 2005-08-17 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2005073229A1 (en) * 2004-01-31 2005-08-11 Sanofi-Aventis Deutschland Gmbh 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
WO2008030120A1 (en) * 2006-09-07 2008-03-13 Auckland Uniservices Limited A method for the fluorescent detection of nitroreductase activity using nitro-substituted aromatic compounds
WO2010064735A1 (en) * 2008-12-05 2010-06-10 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition

Also Published As

Publication number Publication date
WO2010073078A2 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2009053808A3 (en) Histone deacetylase inhibitors
WO2007042912A3 (en) Heterocyclic compounds as pstat3/il-6 inhibitors
TN2011000400A1 (en) Inhibitors of beta-secretase
WO2007054776A3 (en) Stilbene like compounds as novel hdac inhibitors
EA201070864A1 (en) NEW HETEROCYCLIC COMPOUNDS
AU2015293541B2 (en) Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MX2012002752A (en) Heteroaryl compounds as kinase inhibitors.
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
MX2009007260A (en) Cyclized derivatives as eg-5 inhibitors.
UA99361C2 (en) TRIAZINE COMPOUNDS AS PI3 KINASE AND mTOR INHIBITORS
MX358961B (en) C7-fluoro substituted tetracycline compounds.
WO2010073078A3 (en) Heterocyclic compounds as hdac inhibitors
WO2013038429A3 (en) Novel sglt inhibitors
WO2010088050A3 (en) Bicyclic pyrazolo-heterocycles
WO2007109578A3 (en) Substituted gamma lactams as prostaglandin ep2 agonists
WO2007096740A3 (en) Novel cephalosporins
WO2007045962A3 (en) Novel hdac inhibitors
WO2011123946A8 (en) Kinase inhibitors and method of treating cancer with same
MX2009003739A (en) Hydrobenzamide derivatives as inhibitors of hsp90.
IN2014MN01521A (en)
MX2012000231A (en) Novel azabicyclohexanes.
WO2010065512A3 (en) Compounds for treating proliferative disorders
WO2010129057A8 (en) Tetracycline compounds
WO2012172566A3 (en) Novel sglt inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09834189

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09834189

Country of ref document: EP

Kind code of ref document: A2